Intestinal Proteins as Safe CAR-T Cell Therapy Targets for GI Cancers

Time: 1:10 pm
day: Day One


  • Describe GUCY2C, a compartmentalized intestinal protein that may be targetable in GI cancers
  • Address preclinical safety and efficacy data of GUCY2C-directed CAR-T cell therapies
  • Review translational and clinical manufacturing plans as well as clinical trial design